Darby, David; Brodtmann, Amy; Woodward, Michael; Budge, Marc; Maruff, Paul
Background: Ideally putative disease-modifying therapies for Alzheimer's disease (AD) should be tested in patients who have minimal morbidity. Current barriers to such trials in early disease include the lack of disease-specific early biomarkers, insensitivity of quantitative cognitive outcome measures, and expensive trial designs requiring large sample sizes and long duration. This paper describes principles and progress towards a novel trial design that overcomes these problems, utilizing...[Show more]
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.